Notes
Notes - notes.io |
A novel Gram-stain-positive, aerobic, non-spore-forming, and rod-shaped bacterium designated as PW21was isolated from produced water sampled from an oil reservoir in Limbodara, Gujarat, India. Growth occurred at 30-45 °C (optimum 37 °C), at pH 6.5-9.5 (optimum pH 8.5) and in the presence of 0.5-5.0% (w/v) NaCl [optimum, 3% (w/v)]. Phylogenetic analysis based on the 16S rRNA gene sequences showed that PW21T belonged to the class Actinobacteria, order Actinomycetales, family Promicromonosporaceae, and genus Xylanimonas, with the highest sequence similarity to Isoptericola cucumis AP38 (97.95% with 98.8% completeness), followed by Xylanimonas pachnodae NBRC 107,786T (97.82%) and Xylanimonas allomyrinae 2JSPR-7T(97.75%) with 100% completeness for the mentioned strains of Xylanimonas. The genome size of PW21T was 3.4 Mbp with a G+C content of 73.0 mol% (draft genome sequence). The average nucleotide identity (ANI) value of the draft genomes between PW21T and related species were found in between 76.99 and 78.93%. Major cellular fatty acids (> 10% of total fatty acids) of PW21Twere iso-C150, anteiso-C150, and C160. Phylogenetic, physiological, and biochemical characterisation identified strain PW21T (= KCTC 49,338T = JCM 33,795T = MCC 3936T) as a novel species of the genus Xylanimonas, and hence, name Xylanimonas oleitrophica sp. nov. PW21T is proposed.Entamoeba histolytica represents a useful model in parasitic organisms due to its complex genomic organization and survival mechanisms. To counteract pathogenic organisms, it is necessary to characterize their molecular biology to design new strategies to combat them. In this report, we investigated a less-known genetic element, short interspersed nuclear element 2 (SINE2), that is present in this ameba and is highly transcribed and polyadenylated. In this study, we show that in two different nonvirulent strains of E. histolytica, SINE2 is differentially processed into two transcript fragments, that is, a full-length 560-nt fragment and a shorter 393-nt fragment bearing an approximately 18-nt polyadenylation tail. Sequence analysis of the SINE2 transcript showed that a Musashi-like protein may bind to it. Also, two putative Musashi-like sequences were identified on the transcript. Semiquantitative expression analysis of the two Musashi-like proteins identified in the E. histolytica genome (XP_648918 and XP_649094) showed that XP_64094 is overexpressed in the nonvirulent strains tested. The information available in the literature and the results presented in this report indicate that SINE2 may affect other genes, as observed with the epigenetic silencing of the G3 strain, by an antisense mechanism or via RNA-protein interactions that may ultimately be involved in the phenotype of nonvirulent strains of E. histolytica.
Our aim was to develop a novel approach for lung cancer screening among a diverse population that integrates theCenters for Medicare and Medicaid Services (CMS) recommended components including shared decision making (SDM), low-dose CT (LDCT), reporting of results in a standardized format, smoking cessation, and arrangement of follow-up care.
Between October of 2015 and March of 2018, we enrolled patients, gathered data on demographics, delivery of SDM, reporting of LDCT results using Lung-RADS, discussion of results, and smoking cessation counseling. We measured adherence to follow-up care, cancer diagnosis, cancer treatment, and smoking cessation at 2years after initial LDCT.
We enrolled 505 patients who were 57% African American, 30% Caucasian, 13% Hispanic, < 1% Asian, and 61% were active smokers. All participants participated in SDM, 88.1% used a decision aid, and 96.1% proceeded with LDCT. Of 496 completing LDCT, all received a discussion about results and follow-up recommendations. Overall, 12.9% had Lung-RADS 3 or 4, and 3.2% were diagnosed with lung cancer resulting in a false-positive rate of 10.7%. read more All 48 patients with positive screens but no cancer diagnosis adhered to follow-up care at 1year, but only 35.4% adhered to recommended follow-up care at 2years. The annual follow-up for patients with negative lung cancer screening results (Lung-RADS 1and 2) was only 23.7% after one year and 2.8% after 2years. All active smokers received smoking cessation counseling, but only 11% quit smoking.
The findings show that an integrated lung cancer screening program can be safely implemented in a diverse population, but adherence to annual screening is poor.
The findings show that an integrated lung cancer screening program can be safely implemented in a diverse population, but adherence to annual screening is poor.
Most patients with hepatocellular carcinoma (HCC) are ≥ 65years old at diagnosis and ~ 20% present with disease amenable to curative intent surgical therapy. The aim of this study was to examine whether treatment, the demographic variables, and clinical factors could predict 5-year survival among HCC patients.
We included patients, 66years or older, diagnosed with a first primary HCC from 1994 through 2007 in the SEER-Medicare database, and followed up until death or 31 December 2012. Curative intent treatment was defined as liver transplantation, surgery resection, or ablation. We estimated odds ratios (OR) and 95% confidence intervals (CI) for associations with 5-year survival using logistic regression.
We identified 10,826 patients with HCC with mean age 75.3 (standard deviation, 6.4) years. Most were male (62.2%) and non-Hispanic white (59.7%). Overall, only 8.1% of patients were alive 5years post-HCC diagnosis date. Among all patients that survived ≥ 5years, 69.8% received potentially curative treatment. Conversely, patients who received potentially curative treatment represented only 15.7% of patients who survived < 5years. Curative intent treatment was the strongest predictor for surviving ≥ 5years (vs. none/palliative treatment; adjusted OR 8.12, 95% CI 6.90-9.64). While stage at diagnosis and comorbidities were also independently associated with ≥ 5-year survival in HCC patients, these factors did not improve discrimination between short- and long-term survivors.
Curative intent treatment was the strongest predictor for survival ≥ 5years among HCC patients. Given the limited availability of liver transplant and limited eligibility for surgical resection, finding curative intent HCC therapies remain critically important.
Curative intent treatment was the strongest predictor for survival ≥ 5 years among HCC patients. Given the limited availability of liver transplant and limited eligibility for surgical resection, finding curative intent HCC therapies remain critically important.
Homepage: https://www.selleckchem.com/products/semaxanib-su5416.html
|
Notes.io is a web-based application for taking notes. You can take your notes and share with others people. If you like taking long notes, notes.io is designed for you. To date, over 8,000,000,000 notes created and continuing...
With notes.io;
- * You can take a note from anywhere and any device with internet connection.
- * You can share the notes in social platforms (YouTube, Facebook, Twitter, instagram etc.).
- * You can quickly share your contents without website, blog and e-mail.
- * You don't need to create any Account to share a note. As you wish you can use quick, easy and best shortened notes with sms, websites, e-mail, or messaging services (WhatsApp, iMessage, Telegram, Signal).
- * Notes.io has fabulous infrastructure design for a short link and allows you to share the note as an easy and understandable link.
Fast: Notes.io is built for speed and performance. You can take a notes quickly and browse your archive.
Easy: Notes.io doesn’t require installation. Just write and share note!
Short: Notes.io’s url just 8 character. You’ll get shorten link of your note when you want to share. (Ex: notes.io/q )
Free: Notes.io works for 12 years and has been free since the day it was started.
You immediately create your first note and start sharing with the ones you wish. If you want to contact us, you can use the following communication channels;
Email: [email protected]
Twitter: http://twitter.com/notesio
Instagram: http://instagram.com/notes.io
Facebook: http://facebook.com/notesio
Regards;
Notes.io Team